Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.

Former US National Security Advisor Jake Sullivan Talks US-Iran Peace
16:05

Bank of Israel Governor Amir Yaron Talks Israel's Economy
08:35

The RealReal CEO Rati Levesque Talks Luxury Resale Boom
07:42